MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2021006403

Медицинская библиотека · Blood advances · 2022

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors.

Shapiro Amy D, Angchaisuksiri Pantep, Astermark Jan, Benson Gary, Castaman Giancarlo, Eichler Hermann, Jiménez-Yuste Victor, Kavakli Kaan, Matsushita Tadashi, Poulsen Lone Hvitfeldt, Wheeler Allison P, Young Guy, Zupančić-Šalek Silva, Oldenburg Johannes, Chowdary Pratima

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Despite current therapies, there remains an unmet need for treatment for patients with hemophilia. The main parts of two phase 2 trials established clinical proof-of-concept for once-daily, subcutaneous concizumab prophylaxis in patients with hemophilia A/B with inhibitors (HAwI/HBwI; explorer4) and severe hemophilia A without inhibitors (HA; explorer5). Here, we present results from extension parts of these trials, included to evaluate longer term safety and efficacy. Both trials included main (≥24 weeks) and extension (52-102 weeks) parts, with patients receiving concizumab 0.15 mg/kg with potential dose escalation to concizumab 0.20 or 0.25 mg/kg if they experienced ≥3 treated spontaneous bleeding episodes within 12 weeks. Endpoints included annualized bleeding rate (ABR), adverse events (AEs), and occurrence of antidrug antibodies. Thromboembolic events were AEs of special interest. Thirty-six patients with HA, 15 with HAwI, and 10 with HBwI were exposed to concizumab. Estimated ABRs during the main + extension parts at last dose level were 4.8 (95% confidence interval [CI], 3.2-7.2) and 6.4 (95% CI, 4.1-9.9) in explorer4 and explorer5, respectively (spontaneous ABRs were 1.8 [95% CI, 1.2-2.6] and 2.1 [95% CI, 1.3-3.3]). Most AEs were mild, with no deaths, events leading to withdrawal, or thromboembolic events. Anti-drug antibodies developed in 25% of patients and were low titer and transient, with no observed clinical effect in most cases. Results of the main + extension parts of these trials were consistent with results of the main parts. Ongoing phase 3 trials will further evaluate concizumab as a once-daily, subcutaneous treatment across hemophilia subtypes. These trials were registered at www.clinicaltrials.gov as #NCT03196284 and #NCT03196297.

Для цитирования: Shapiro Amy D, Angchaisuksiri Pantep, Astermark Jan, Benson Gary, Castaman Giancarlo, Eichler Hermann, Jiménez-Yuste Victor, Kavakli Kaan, Matsushita Tadashi, Poulsen Lone Hvitfeldt, Wheeler Allison P, Young Guy, Zupančić-Šalek Silva, Oldenburg Johannes, Chowdary Pratima. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors.. Blood advances. 2022. DOI: 10.1182/bloodadvances.2021006403.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.